CoChat

Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice

Open access
Kamezaki, Michitsugu, Kusaba, Tetsuro, Komaki, Kazumi, Fushimura, Yohei, Watanabe, Noriko, Ikeda, Kisho, Kitani, Takashi, Yamashita, Noriyuki, Uehara, Masahiro, Kirita, Yuhei, Shiotsu, Yayoi, Sakai, Ryosuke, Fukuda, Takuya, Yamazaki, Masahiro, Fukui, Michiaki, Matoba, Satoaki, Tamagaki, Keiichi · 2018 · Scientific Reports
Cited by 73

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Clinical and experimental studies have shown that sodium glucose co-transporter 2 inhibitors (SGLT2i) contribute to the prevention of diabetic kidney disease progression. In order to clarify its pharmacological effects on the molecular mechanisms underlying the development of diabetic kidney disease, we administered different doses of the SGLT2i, ipragliflozin, to type 2 diabetic mice. A high-dose ipragliflozin treatment for 8 weeks lowered blood glucose levels and reduced urinary albumin excretion. High- and low-dose ipragliflozin both inhibited renal and glomerular hypertrophy, and reduced NADPH oxidase 4 expression and subsequent oxidative stress. Analysis of glomerular phenotypes using glomeruli isolation demonstrated that ipragliflozin preserved podocyte integrity and reduced oxidative stress. Regarding renal tissue hypoxia, a short-term ipragliflozin treatment improved oxygen tension in the kidney cortex, in which SGLT2 is predominantly expressed. We then administered ipragliflozin to type 1 diabetic mice and found that high- and low-dose ipragliflozin both reduced urinary albumin excretion. In conclusion, we confirmed dose-dependent differences in the effects of ipragliflozin on early diabetic nephropathy in vivo. Even low-dose ipragliflozin reduced renal cortical hypoxia and abnormal hemodynamics in early diabetic nephropathy. In addition to these effects, high-dose ipragliflozin exerted renoprotective effects by reducing oxidative stress in tubular epithelia and glomerular podocytes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-018-22229-5

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 73

Metadata

Authors
Kamezaki, M., Kusaba, T., Komaki, K., Fushimura, Y., Watanabe, N., Ikeda, K., Kitani, T., Yamashita, N., Uehara, M., Kirita, Y., Shiotsu, Y., Sakai, R., Fukuda, T., Yamazaki, M., Fukui, M., Matoba, S., & Tamagaki, K.
Venue
Scientific Reports
Published
2018-03-05
Volume
8
Issue
1
Pages
4029-4029
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2796903473
Cited by
73
References
14
FWCI
5.99
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. https://app.cochat.ai/papers/10.1038/s41598-018-22229-5
The paper
Kamezaki, M., Kusaba, T., Komaki, K., Fushimura, Y., Watanabe, N., Ikeda, K., Kitani, T., Yamashita, N., Uehara, M., Kirita, Y., Shiotsu, Y., Sakai, R., Fukuda, T., Yamazaki, M., Fukui, M., Matoba, S., & Tamagaki, K. (2018). Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. Scientific Reports. https://doi.org/10.1038/s41598-018-22229-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.